Introduction
Recently many papers on association of angiotensin converting enzyme (ACE) gene polymorphism with the onset and progression of nephropathies have been published (Sharnova, Tsygin and Tikhomirov, 2006) . According to Tsygin et al. (2005) , DD genotype of ACE gene is a predisposing factor for chronic kidney disease (CKD) terminating nephrotic syndrome in children with type 1 diabetes mellitus, while ACE gene II genotype upon diabetic nephropathy (DN) appears to be a protective one (Shestakova, Nosikov and Vikulova 2007; Azar, Zalloua, Medlej, and Halabi 2001; Boright, Paterson, Mirea, Bull et. al., 2005; Ng, Tai, Koh, and Chia 2005) . Case-control studies conducted in various race populations demonstrated interpopulation differences in distribution of frequency of I/D, an ACE gene polymorphic marker (Arfa, Abid, Nouira, Elloumi-Zghal et al., 2008) . The highest and the lowest frequencies of the insertion have been registered in the Mongoloids (60.9%) and in the Negroids (39.7%), respectively, mean values of the marker can be seen in the Caucasians (43.8%) (Ortega-Pierres, Gómez Garcia and Rodrigues-Ayala, 2007) . For the first time we managed to show an association between ACE polymorphism and diabetic nephropathy in children and adolescents with type 1 diabetes mellitus (Rakhimova, Mukhamedov and Nurmatov, 2007; Rakhimova and Sadykova, 2009 ). Urinary neutral alpha-glucosidase is known to be a biochemical marker of subclinical renal disease in diabetes mellitus (Akhrarkhodzhaeva, 2005; Lebedeva, Balkarov and Lukicheva, 1998) . For the first time we managed to demonstrate significant increase in its level in proportion to accumulation of ACE gene D allele in genotype. Urinary neutral α-glucosidase content in patients with ID and DD genotypes was found confidently different from the one in patients with II genotype, to show ACE genetic dependence of the parameter (Rakhimova et al., 2007; Rakhimova and Sadykova, 2009) . Some authors report on relationship between efficacy of ACE inhibitors for treatment of DN and ACE gene polymorphism (Böger, Götz, Krüger, Hösl, and Schmitz, 2005; Ruggenenti, Bettinaglio, Pinares, and Remuzzi, 2008) . Some studies demonstrated limitation in renoprotective effect of ACE inhibitors in patients with CKD homozygous for ACE gene D allele, proteinuria and renal insufficiency in these patients being found higher than in the individuals homozygous for I allele (Luther, Bantis, Ivens et al., 2003) . EUCLID Randomized Controlled Trial of Lisinopril in IDDM demonstrated dependence of intensity of lisinopril antriproteinuric effect on ACE gene I/D polymorphism. As compared with placebo group albuminuria level was found reducing in patients with II genotype taking lisinopril more significantly (by 51.3%) than in those with ID and DD genotypes (by 14.8% and 7.7%, respectively) (Penno, Chatuvedi, Talmud et al., 1998) . No confident differences in clinical and laboratory parameters, including arterial pressure and HbA1c level, by a genotype were found. ACE gene polymorphism was established to determine ACE level in blood and tissues. Thus, low level of the enzyme is typical of ACE gene II genotype, its nearly 2 times higher level being demonstrated in patients with DD genotype and intermediate one in heterogyzotes (Amann, Tinzmann and Angelkort, 2003) . But most studies were conducted in the adult diabetic patients with clinical DN. No evidence for similar studies in normoalbuminuric children and adolescents with subclinical type 1 diabetes mellitus treated with perindopril by ACE genotype was found. The work was initiated to assess efficacy of perindopril (prestarium) in normoalbuminuric patients with type 1 diabetes mellitus by ACE genotype in the primary intervention of diabetic nephropathy.
Materials and methods
We examined 22 normoalbuminuric patients with type 1 diabetes mellitus aged from 12 to 17 (mean age 14.8±0.26 years) with DN duration of 10 and more years (mean 10.5±0.35 years) hospitalized at the pediatric department of the Center for the Scientific and Clinical Studies of Endocrinology, Uzbekistan Public Health Ministry. By ACE polymorphism the patients were divided into two groups, the first and the second groups including elevenby-eleven carriers of II genotype and DD genotype, respectively (Table 1) . No differences were observed in clinical characteristics of the groups by age as well as by diabetes onset, duration and compensation. Written consent was obtained from all participants. . Parallel to insulin therapy all patients were prescribed with perindopril (prestarium), an ACE inhibitor (Servier, France), in the dose of 2.5 mg/day to be followed up for 6 months.
Results and discussion
Children and adolescents with II genotype receiving perindopril demonstrated respective reduction in daytime systolic arterial pressure (dSAP) and diastolic arterial pressure (dDAP) by 4.2% and 3.6%, respectively, confident reduction in heart rate by 6.4% being registered as well (Table 2 ). Nocturnal changes in arterial pressure were not so intensive, nSAP and nDAP values being reduced by 0.8% and 1.4%, respectively. In DD genotype carriers post-therapy SAP and DAP values remained unchanged as compared with those before therapy both in daytime and at night. Insignificant reductions in daytime SAP by 0.8% and nocturnal DAP by 0.7% as well as heart rate by 1.3% were observed. Note: P1 is a confidence in relation to patients with II genotype before therapy Some coagulogram parameter changes within the reference range took place. Thus, in the first group pre-and post-therapy thrombotest degree was 5.27±0.1 degree and 5.18±0.1 degree, respectively (normal range IV-VI degree). Basal and post-therapy values of blood fibrinolytic activity were 15.3±0.8% and 14.9±0.6%, respectively, (normal range 15-25%), fibrinogen level changing from 3.02±0.2 g/l to 3.08±0.2 g/l (normal range 2-4 g/l). Insignificant reductions versus basal thrombotest degree (5.4±0.1 degree), fibrinogen level (3.25±0.3 g/l) and blood fibrinolytic activity (16.2±1.24%) were found in the second group of patients, to be 5.27±0.1 degree, 3.17±0.3 g/l and 16.2 ±1.24%, respectively. Thus, coagulogram parameters in children and adolescents with type 1 diabetes mellitus receiving perindopril remained normal demonstrating no dependence on genotype. Lipid and carbohydrate parameters showed a tendency to improvement in the first group of patients manifesting in total cholesterol reduction by 4.4% and confident HbA1c decrease by 16.7% (Table 3 ). In patients with DD genotype HbA1c and total cholesterol levels reduced by 4.7% and 0.8%, respectively, thus being less intensive. Reduction in proteinuria by 7.1% (to 11.8±0.8 mmol/l) and by 6.8% (to 12.3±0.8 mmol/l) was respectively found in patients with II and DD genotypes. As to glomerular filtration rate (GFR) and creatinine, the parameters in the first group of patients reduced by 9.2% and 4.6%, respectively, insignificantly decreasing in the second group (by 2.2% and 1.2%, respectively). Increase in urinary enzymes upon diabetes mellitus is known to be associated with disorders in all types of metabolism, tissue hypoxia and acid-base disequilibrium taking place due to absolute or relative deficit of insulin (Bondar, Pupyshev and Klimontov 2000; Shamansurova, Akhrarkhodzhaeva, Akbarov, and Kasymov, 2004) . Study on dynamics of urinary neutral alpha-glucosidase by genotypes of patients with type 1 diabetes mellitus revealed confident reduction by 63.6% in activity of the parameter in patients with II genotype receiving perindopril as compared with DD genotype carriers was registered (Table 4) . It should be noted that basal urinary alpha-glucosidase activity in patients with DD genotype was confidently 3.5 times higher (P=0.0001) than in II genotype carriers. In the second group of patients alpha-glucosidase activity was found confidently reducing by 10.5%, though being 8.5 times higher (P4=0.0001) as compared with the post-therapy values in the first group. Note: P1 is a confidence in relation to patients with II genotype before therapy, P2 is a confidence in relation to patients with II genotype before and after therapy, P3 is a confidence in relation to patients with DD genotype before and after therapy, P4 is a confidence in relation to patients with II and DD genotypes after therapy
The findings from our study demonstrated that therapy with perindopril (prestarium) in normoalbuminuric children and adolescents with type 1 diabetes mellitus, carriers of ACE gene II genotype, as compared with the carriers of DD genotype. facilitated more confident improvement in hemodynamic parameters, such as, arterial pressure and glomerular filtration rate, biochemical parameters, such as, total cholesterol and HbA1c, contributing to amelioration of alpha-glucosidase, a parameter of endothelial dysfunction of distal renal tubules. The findings can serve as a basis for determination of ACE gene polymorphism in all Uzbek children and adolescents with type 1 diabetes mellitus and prescription of perindopril, an ACE inhibitor, at the stage of normoalbuminuria for optimization of intervention and therapy of diabetic nephropathy.
Conclusion
6-month therapy with perindopril in diabetic children and adolescents with II genotype, preferably, facilitates moderate reduction of systolic and diastolic arterial pressure within normal range by 4.2% and 3.6%, respectively, confident reduction in heart rate by 6.4%. The therapy in normoalbuminuric children and adolescents with type 1 diabetes mellitus contributes to more significant reduction in total cholesterol in patients with II genotype (by 4.4% versus 0.8% in those with DD genotype) and confident decrease in HbA1c (by 16.7% versus 4.7% in patients with DD genotype). Significant reduction in the activity of alpha-glucosidase was observed in patients with II genotype (by 63.6%) and in those with DD genotype (by 10.5%), though being 8.5 times higher after therapy in the lastmentioned. The therapy resulted in decrease of proteinuria and delay of renal function impairment (GFR and creatinine by 9.2% and 4.2%, respectively) mainly in patients with II genotype, contributing to prevention of DN onset or slowdown of its progression. Perindopril in low doses is recommended to treat normoalbuminuric children and adolescents for optimization of intervention and therapy of diabetic nephropathy.
